Kap 16 Kemisk stabilitet i Homepump

Transkript

1 Kap 6 Kemisk stabilitet i Homepump Acyklovir Na 0 mg/ml 0 mg/ml 0 dygn 0 dygn 0 dygn Albumin 0 mg/ml RTU 5 6 Amikacin SO4 0,5 0 mg/ml dygn 0 dygn dygn 7, 9 Aminophylline dygn dygn 9 6 Amfotericin B** 0, mg/ml 0 dygn Ampicillin Na 0,0 0,0 mg/ml h h dygn dygn Amipicillin Na/ Sulbactam Na Azitromycin Azlocillin 0/ dygn mg/ml / 50 mg/ml Aztreonam, 6,7 mg/ml 0 mg/ml 5 60 mg/ml 60 mg/ml 60 mg/ml 5 50 mg/ml Bleomycin SO4,07 IU/ml Bensylpenicillin Bupivacain HCL Bupivacain HCL/ Ceftriaxone 0 60 mg/ml, 0,065 0, 0, +,7 mg/ml ab. /WFI buffrat i 0,0 M Nacitrat /RTU 5 dygn (7 0 C) dygn dygn 7 dygn 5, h Bupivacain HCL/ Cefazolin Bupivacain/ Metylparaben 0, + 7 mg/ml ab.,5 mg, / mg/ml dygn Bupivacain/ Dexametasonfosfat 0,4 mg/ml 5 dygn Okt Kap 6 Kemisk stabilitet Sid (0)

2 Bupivacain/ Ketorolac/ Morfin 0,4 mg/ml/ 0,0 mg/ml 5 dygn 9 Carbenicillin 40 mg/ml dygn 4 v Caspofungin 0, 0, 60 h Cefazolin Na 5 0 dygn Cefepim 40 mg/ml 5 dygn Cefonocid dygn v Cefoperazone Na 50 mg/ml / 5 dygn v,9 Cefotaxim 0 / v Cefotaxim Na 6,67 mg/ml v Cefotetan disodium 0 40 mg/ml / 4 dygn v 60 dygn Cefteolozan/ Tazobactam 50 mg 500 mg / 0 dygn 40 Cefotiam / Cefoxitin Na 0 mg/ml / dygn, 9 Cefpirome SO4 dygn Ceftazidim 5 0 mg/ml 5 40 mg/ml 60 mg/ml 5 40 mg/ml h dygn 4 dygn 5 6, Ceftizoxime Na 40 mg/ml / 4 h Okt Kap 6 Kemisk stabilitet Sid (0)

3 Ceftriaxon Na 0 00 mg/ml 0 40 mg/ml 0 40 mg/ml / 7 h 7 h 0 dygn 6 v. Cefuroxim 0 mg/ml / 6 mån., 9 Chirocain,, RTU 0 Cephalotin Na h 4 dygn 6 v Cephapirin Na 0 dygn v Cephradine 0 mg/ml 0 h dygn 6 v Cimetidin HCL 6 mg/ml 4 h dygn 4 v Ciprofloxacin Cisplatin Cloxacillin Na Colistimethate Na ColyMycin Colistin Cyclofosfamid Cytarabin Daptomycin Desferoxamin Desferoxamin Mesylate 0,5 mg/ml mg/ml 0, mg/ml 0,05 0, 0, mg/ml 550 mg/ml 540 mg/ml 0 mg/ml 75 mg colistin/ml, mg colimycin/ml 0,050,075MU/ml 4, 0,0 mg/ml 0,, 0, mg/ml,5 0,0 mg/ml 0, mg/ml 500 mg/ml 5 60 mg/ml 7 mg/ml 59 / RTU / dygn 4 dygn 4 h dygn 4 5 dygn dygn / / / / / 4 h dygn 9 dygn 7 dygn 9 4 h dygn 5 dygn 4 h dygn 0 dygn, 9 6,9 dygn dygn Dexametason 0, mg/ml 4 h Okt Kap 6 Kemisk stabilitet Sid (0)

4 Dexametason fosfat 0,67 mg/ml 4 Doxorubicin mg/ml Doxorubicin HCI 0, mg/ml mg/ml 4 h Doxycyklin 0, mg/ml mg/ml / 4 h dygn v. Ertapenem Na 0 mg/ml 0 mg/ml h h 5 dygn 9 dygn 6 6 Erytromycin h v Etoposid Flukloxacillin 0, 0,4 mg/ml 0 mg/ml 0 mg/ml mg/ml Väntar på resultat 9 dygn 4 dygn 6,9 6,9 6,9 Flukonazol mg/ml RTU* Fluorouracil, 5Fu Flurouracil + Sodiumfolinat Foskarnet Na 50 mg/ml 50 mg/ml 50 mg/ml RTU* RTU* veckor 45 dygn 45 dygn 45 dygn 45 dygn. 6 +, mg/ml mg/ml 4 mg/ml / RTU* Fosfomycin Na mg/ml 4 4 Furosemid 0 mg/ml 0.5, 5, 0 mg/ml mån 4 dygn+ 5 +4h 5 Ganciklovir Na Gemcitabin Hydroklorid.4, 4, 7 mg/ml 0 mg/ml Väntar på resultat 0., 0, mg/ml 0 dygn 5 dygn 5 dygn 65 dygn 5 Gentamicin SO4 0, mg/ml 0,6 mg/ml mg/ml 4, mg/ml 4, mg/ml 0, 4 mg/ml / 4 dygn dygn 4, 7 dygn dygn 5,9 Okt Kap 6 Kemisk stabilitet Sid 4(0)

5 Granisetron HCI 0,0 mg/ml 7 Heparin Na U/ml 500 IU/ml veckor veckor Ifosfamid 0,6 mg/ml 0 mg/ml 9 dygn 6 veckor Imipenem ImipenemCilastin Na 0 h dygn Kalciumfolinat 4 mg/ml Klindamycin PO4 0 mg/ml 6, 9, mg/ml 6 mg/ml mg/ml 6 dygn 5 dygn 0 dygn dygn 0 dygn v. Levofloxacin / 7 h 6 mån. Lidocain HCL 0 mg/ml Lincomycin HCL 0 mg/ml dygn, Mesna Meropenem Vid uppvärmning från kyl till rumstemp minskar koncentrationen av Meropenem med % 40 mg/ml 4 mg/ml 0 mg/ml 0 mg/ml 0 mg/ml 0 6 h h h 5 4 dygn+6 h dygn+6 h 5 dygn h 5 dygn 5 5 dygn, 90%, 9% 5 dygn, 9% dygn, 90% 5 dygn, 4% Meticillin Na 4 dygn 4 v Metotrexat Na 0,0 mg/ml,5, 05 dygn Metronidazol RTU 0 dygn Okt Kap 6 Kemisk stabilitet Sid 5(0)

6 Metylprednisolon Na 0 mg/ml Mezlocillin Na 4 h 4 v Minocyklin 0, mg/ml dygn Mitoxantron 0,04 mg/ml 0,6 mg/ml dygn dygn Morfin HCL 0 40 mg/ml RTU 6 v. 6 v. 5 Morfin SO4 dygn Moxolactam Na 4 dygn 6 mån Natriumklorid 9 mg/ml 5 dygn 5 dygn Nafcillin Na Netilmicin 0 mg/ml 0, mg/ml mg/ml 4 mg/ml dygn 7 h dygn Ofloxacin 0,4 4 mg/ml / 7 h 6 mån. 9 Ondansetron HCL 0,00, mg/ml / Oxacillin 0 00 mg/ml dygn dygn 7 Paclitaxel 6 mg/ml / Pamidronsyra Na Pamidronate SO4 0,0 mg/ml 0,0 mg/ml 0,4 mg/ml 0,5 0,60 mg/ml 9 dygn dygn dygn 4 h Penicillin GK 0,000 U/ml,00 U/ml 4 dygn Piperacillin 0, mg/ml Piperacillin Na Piperacillin Na/ Tazobactam Na 0,0 0,0 0 mg/ml 0 0 mg/ml +, mg/ml mg/ml , 0 mg/ml 40 0 mg/ml NaOH NaOH 5 dygn 9 dygn 5 dygn dygn dygn 4 v., 9 Prednisolon 0,67 mg/ml 0 dygn Okt Kap 6 Kemisk stabilitet Sid 6(0)

7 Quinpristin/ Dalfopristin Ranitidin HCI 0 mg/ml 5 h 54 h 0 0,5 mg/ml /, Rifampicin 0,7 Ropivacain HCL mg/ml 7, 45 dygn Ropivacain/Ketorolak mg/ml Teicoplanin 4 mg/ml dygn Terbutalin SO4 Trimetoprim/ sulfametoxazol 4 µg/ml 50, 00 µg/ml 500 µg/ml 50 µg/ml WFI dygn dygn 0 5 dygn 0 5 dygn mg/ml 4 h Ticarcillin Disodium Klavulanate K mg/ml Tobramycin SO4 0, 0 mg/ml 0 mg/ml Vancomycin 4 mg/ml Vancomycin HCI 5 4 h dygn 6 dygn 6,9 Venofer mg/ml dygn dygn Vinkristin 0,0 mg/ml 0,05 mg/ml 7 7 Fotnoter: * RTU = "Ready to use" = färdig att användas ** Uppmärksamhet på substansens utfällningsrisk beroende av beredning, lagring, koncentration, PH och lösningsmedel. Studie utförd på jämförbar behållare. Uppmärksamma ämnets risk för utfällning, vilket kan bero på preparation, lagring, koncentration ph el. lösningsmedel. Kylförvaring + 6 h rumstemp. Okt Kap 6 Kemisk stabilitet Sid 7(0)

8 4 Risk för utfällning i kylskåp. 5 Kyla=5 C 6 Licenspreparat 7 + h i rumstemperatur + h i 7 C + h i rumstemperatur + h i 7 C 9 i C, dygn i 4 C 0 + i 7 C Mixtur med Doxorubicin,4 mg/ml + i 7 C + i 5 0 C 4 + i 4 0 C + i 5 0 C 5 0 C i mörker 6 Hög viskositet ger långsammare infusion. 0 ml i SE (00 ml, 50 ml/h) går in på 5 h. 7 + i rumstemperatur Stabilitetsdata refererar endast till kemisk stabilitet, ej mikrobiologisk stabilitet. 9 + i rumstemperatur + h i 7 C Referenslista: Ref. Ref. Ref. Ref. 4 Ref. 5 Ref. 6 Ref. 7 Ref. Ref. 9 Ref. 0 Ref. Ref. Ref. Testing completed by Beckman Industrial Corp., U.S.A. Testing completed by Pyramid Laboratories, U.S.A. Testing completed by Centre Antoine Lacassagne, France. Testing completed by Karolinska Hospital, Dept. of Clinical Pharmacology, Sweden. Testing completed by Nycomed Pharma, Norway. Jhee SS et al. Stability of ondansetron hydrochloride in a disposable, elastomeric infusion device at 4 C. Am J Hosp Pharm. 99; 50:9. Chung KC, Chin A, Gill MA. Stability of granisetron hydrochloride stored in a disposable elastomeric infusion device. Am J HealthSyst Pharm. 995; 5:54. Trissel, Lawrence A. Handbook on Injectable Drugs. Physicians Desk Reference, 55th edition, Medical Economics Company, Oradell, NJ 0. Manufacturer s Product Information. Stewart S, Warren F, Johnson S, Golante L. Stability of Ranitidine in Intravenous As mixtures stored frozen, refrigerated, and at room temperature. Sept. 990: 47:445 Das Gupta, V, Stewart, KR, Nohria, S. Stability of Vancomycin HCI in 5% Dextrose and 0.9% Sodium Chloride Injections. American Journal of Hospital Pharmacy, July 6: 4:797. Testing completed by National Corporation of Swedish Pharmacies, Stockholm, Sweden. Okt Kap 6 Kemisk stabilitet Sid (0)

9 Ref. 4 Ref. 5 Ref. 6 Ref. 7 Ref. Ref. 9 Ref. Ref. & Ref. Department of Pharmacy and Pharmacology, University of Bath, England. Pharmacy Academic Practice Unit, University of Derby, United Kingdom. Testing completed by Fresenius Kabi Limited, Cardiff University, United Kingdom. McEvoy Gerald, AHFS Drug Information 9. American Society of Hospital Pharmacists, 99. Stendal, Tove. et al. Drug stability and pyridine, generation in ceftazidime injection stored in an elastomeric device. AMJ Health System Pharmacy. Oct. 99:55:6 65. Cardiff data, Se Cardiff stab data Data on file Solann AB Technical Bulletin: 0705A, 0706A Mars 05, Fresenius Kabi (UK) Ltd. Contact: Tony Rigden Ref. Smith D. Am J HealthSyst Pharm 6(6) 665, 04 Ref. 4 Apoteksbolaget Produktion & Lab 995 Ref. 5 Juli 06, MSD. Kontakta Solann AB för mer information. Ref. 6 Am Journal of Hospital Pharmacy, vol 4, dec 6. Ref. 7 Ref. Ref. 9 Teknisk Bulletin 05A Teknisk Bulletin 05075A Teknisk Bulletin Ref. 0 Testing completed at Sykehusapoteket, Trondheim, Norway, Nov 0 Ref. Ref. Ref. Ref. 4 Testing completed by Prof. G. Houin, Hospital Rangueil, France. Testing completed by Prof. M. Allwood, University of Derby, UK. Testing completed by the pharmacy, Maasland Hospital, Sittard, the Netherlands, Aug 0 Teknisk Bulletin 056A Ref. 5 Sjukhusapoteket Universitetssjukhuset Linköping, 9. Ref. 6 Ref. 7 Ref. Ref. Ref. Ref. 40 Carryn et al. Temocillin stability in elastomeric devices (JAC00) Data on file Halyard Health Data on file Cubist Pharmaceuticals Data on file Halyard Health Data on file Solann NCBI Curr Ther Res Clin Exp. 7; 4: 5. Joseph Terracciano, PhD, et al Okt Kap 6 Kemisk stabilitet Sid 9(0)

10 Okt Kap 6 Kemisk stabilitet Sid 0(0)